 This study developed a novel nanospunge therapeutic medication system, AS1411 at Antomiya, 21 at DOX, for treating colon cancer. This system utilized rolling-circle transcription, RCT, to create a nanospunge loaded with antimicroRNA, 21, and DOXerubicin, DOX. The atom-loaded nanospunge was then used to target cancer cells, resulting in increased cell viability, cell apoptosis, and decreased ROS production. Transcriptomic analysis showed that the nanospunge drug could induce cell cycle arrest and apoptosis through the mitotic metaphase and anaphase phases, as well as the smack-mediated dissociation of the IAP, caspase complexes. Overall, this system provided a targeted, efficient, and cost-effective method for treating colon cancer. This article was authored by Liézhu, G. U. Han, Hao Yu, and others. We are article.tv, links in the description below.